Ibnsina Pharma, Egypt’s largest pharmaceutical distributor posts $19 million profit in 2025

Ibnsina Pharma, Egypt’s largest pharmaceutical distribution company, has reported a strong financial performance for the 2025 fiscal year, posting a net profit of EGP952 million ($19 million) as revenue surged amid rising demand for pharmaceuticals and continued expansion across its distribution network.

The Cairo-listed company recorded net revenue of EGP76.6 billion ($1.53 billion) in 2025, representing a 37.17% year-on-year increase from EGP55.84 billion ($1.11 billion) a year earlier. The growth underscores Ibnsina Pharma’s dominant position in Egypt’s fast-growing healthcare market, where it has maintained the leading distribution market share for the third consecutive year.

Revenue growth driven by core distribution
Ibnsina Pharma’s growth was largely fueled by its core retail distribution business, which supplies pharmacies across Egypt. Retail sales climbed 36.3% to EGP39.8 billion ($793.03 million), accounting for nearly half of the company’s total revenue.

The wholesale segment also delivered solid growth, expanding 33.8% to EGP24.8 billion ($494.01 million), while revenues from tenders and private hospitals surged 52.2% to EGP15 billion ($298.8 million), reflecting stronger institutional demand.

The company reported gross profit of EGP6.4billion ($127.52 million), up 47% year-on-year, lifting its gross profit margin to 8.4% from 7.9% previously. Ibnsina Pharma said the strong earnings growth reflects economies of scale as its expanding distribution network spreads operational costs across a wider revenue base. Operational expansion continued during the year. 

Strengthening balance sheet
Founded in 2001, Ibnsina Pharma distributes products from more than 350 Egyptian and multinational pharmaceutical manufacturers to over 50,000 customers. The Mahgoub and Abdel Gawad families remain key founding shareholders and long-term controlling investors, holding stakes of 10.1% and 15.6%, respectively. Both families have remained central to the company’s governance as it evolved into one of Egypt’s most influential pharmaceutical distributors.

The pharma company strengthened its balance sheet through a deleveraging strategy. Net debt declined to EGP5.5 billion ($109.58 million) by the end of 2025 from a peak of EGP7.3 billion ($145.45 million) earlier in the year, while the debt ratio fell to 18% from 20% in 2024. Total assets rose 26.44% to EGP36.21 billion ($721.41 million) from EGP28.64 billion ($570.54 million), while retained earnings increased to EGP2.34 billion ($46.55 million) from EGP1.58 billion.

Ibnsina Pharma operated 72 distribution sites nationwide, serving nearly 53,000 clients across pharmacies, hospitals, and wholesalers. Its delivery fleet expanded to 1,091 vehicles to support rising demand. With more than 8,000 employees, the company remains a critical link in Egypt’s healthcare supply chain, serving tens of thousands of pharmacies, hospitals, and healthcare providers nationwide.